News
-
-
PRESS RELEASE
Valneva Announces Successful Outcome of its Annual General Meeting, Confirms FY 2025 guidance
Valneva SE announces successful outcome of its Annual General Meeting approving 2024 financial statements and appointing Dr. Gerd Zettlmeissl to the Board. Confirms FY 2025 guidance. Shares held steady on Nasdaq & Euronext Paris -
-
-
-
PRESS RELEASE
Valneva Announces Availability of Documentation for its Combined Shareholder Meeting and Provides Corporate Update
Valneva SE announces availability of documentation for its Combined Shareholder Meeting on June 25, 2025, along with corporate update and executive departure. Details on accessing meeting documents and farewell to Mr. Grimaud -
-
-
-
PRESS RELEASE
Valneva Provides Update on Recommendation for Use of Its Chikungunya Vaccine by French Authorities
Valneva SE provides an update on the recommendation for the use of its Chikungunya vaccine by French authorities, focusing on adverse events in elderly people. The company is collaborating with regulators on next steps